• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

克拉霉素和吡嗪酰胺对人巨噬细胞内结核分枝杆菌的协同活性。

Synergistic activities of clarithromycin and pyrazinamide against Mycobacterium tuberculosis in human macrophages.

作者信息

Mor N, Esfandiari A

机构信息

Charles R. Drew University of Medicine and Science, Los Angeles, California 90059, USA.

出版信息

Antimicrob Agents Chemother. 1997 Sep;41(9):2035-6. doi: 10.1128/AAC.41.9.2035.

DOI:10.1128/AAC.41.9.2035
PMID:9303411
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC164062/
Abstract

The combination of clarithromycin and pyrazinamide was found to be synergistic against Mycobacterium tuberculosis in human macrophages. MICs were four- to eightfold lower for this combination than they were for either drug alone. Clarithromycin and rifampin, however, had only an additive effect.

摘要

在人类巨噬细胞中，发现克拉霉素和吡嗪酰胺联合使用对结核分枝杆菌具有协同作用。该联合用药的最低抑菌浓度（MIC）比单独使用任何一种药物时低四至八倍。然而，克拉霉素和利福平仅具有相加作用。

相似文献

1
Synergistic activities of clarithromycin and pyrazinamide against Mycobacterium tuberculosis in human macrophages.克拉霉素和吡嗪酰胺对人巨噬细胞内结核分枝杆菌的协同活性。
Antimicrob Agents Chemother. 1997 Sep;41(9):2035-6. doi: 10.1128/AAC.41.9.2035.
2
Antituberculosis activity of clarithromycin.克拉霉素的抗结核活性。
Antimicrob Agents Chemother. 1995 Dec;39(12):2692-5. doi: 10.1128/AAC.39.12.2692.
3
In vitro activities of fourteen antimicrobial agents against drug susceptible and resistant clinical isolates of Mycobacterium tuberculosis and comparative intracellular activities against the virulent H37Rv strain in human macrophages.十四种抗菌药物对药物敏感和耐药的结核分枝杆菌临床分离株的体外活性以及对人巨噬细胞中强毒株H37Rv的细胞内活性比较
Curr Microbiol. 1996 Sep;33(3):167-75. doi: 10.1007/s002849900095.
4
Determination of in vitro synergy when three antimicrobial agents are combined against Mycobacterium tuberculosis.三种抗菌药物联合抗结核分枝杆菌时的体外协同作用测定
Int J Antimicrob Agents. 2005 Oct;26(4):292-7. doi: 10.1016/j.ijantimicag.2005.05.005.
5
Synergistic activities of clarithromycin and antituberculous drugs against multidrug-resistant Mycobacterium tuberculosis.克拉霉素与抗结核药物对耐多药结核分枝杆菌的协同活性。
Antimicrob Agents Chemother. 1995 Jul;39(7):1542-5. doi: 10.1128/AAC.39.7.1542.
6
The molecular basis of resistance to isoniazid, rifampin, and pyrazinamide in Mycobacterium tuberculosis.结核分枝杆菌对异烟肼、利福平及吡嗪酰胺耐药性的分子基础
Respir Res. 2001;2(3):164-8. doi: 10.1186/rr54. Epub 2001 Apr 5.
7
[Bactericidal therapy in patients with tuberculosis].[结核病患者的杀菌治疗]
Probl Tuberk Bolezn Legk. 2004(3):21-6.
8
The Combination Rifampin-Nitazoxanide, but Not Rifampin-Isoniazid-Pyrazinamide-Ethambutol, Kills Dormant Mycobacterium tuberculosis in Hypoxia at Neutral pH.利福平-硝唑尼特联合用药，而非利福平-异烟肼-吡嗪酰胺-乙胺丁醇，可在中性 pH 缺氧条件下杀死休眠状态的结核分枝杆菌。
Antimicrob Agents Chemother. 2019 Jun 24;63(7). doi: 10.1128/AAC.00273-19. Print 2019 Jul.
9
Characterizing the Effects of Glutathione as an Immunoadjuvant in the Treatment of Tuberculosis.表征谷胱甘肽作为抗结核免疫佐剂的作用。
Antimicrob Agents Chemother. 2018 Oct 24;62(11). doi: 10.1128/AAC.01132-18. Print 2018 Nov.
10
[MICs and MBCs of levofloxacin, clarithromycin, and KRM-1648 for Mycobacterium tuberculosis and M. avium complex residing in MONO-MAC-6 human macrophage-like cell and A-549 human type II alveolar epithelial cell lines].左氧氟沙星、克拉霉素和KRM-1648对驻留在MONO-MAC-6人巨噬细胞样细胞和A-549人II型肺泡上皮细胞系中的结核分枝杆菌和鸟分枝杆菌复合体的最低抑菌浓度和最低杀菌浓度
Kekkaku. 1999 Jul;74(7):571-7.

引用本文的文献

1
Tuberculosis chemotherapy: current drug delivery approaches.结核病化疗：当前的药物递送方法。
Respir Res. 2006 Sep 19;7(1):118. doi: 10.1186/1465-9921-7-118.
2
Drug treatment for tuberculosis during pregnancy: safety considerations.孕期结核病的药物治疗：安全性考量
Drug Saf. 2001;24(7):553-65. doi: 10.2165/00002018-200124070-00006.
3
Genetics and pulmonary medicine. 5. Genetics of drug resistant tuberculosis.遗传学与肺病学。5. 耐多药结核病的遗传学
Thorax. 1998 Sep;53(9):793-7. doi: 10.1136/thx.53.9.793.

本文引用的文献

1
Combined effect of pyrazinamide and ofloxacin within the human macrophage.吡嗪酰胺和氧氟沙星在人巨噬细胞内的联合作用
Tuber Lung Dis. 1996 Dec;77(6):491-5. doi: 10.1016/s0962-8479(96)90045-3.
2
Clarithromycin is inactive against Mycobacterium tuberculosis.克拉霉素对结核分枝杆菌无活性。
Antimicrob Agents Chemother. 1995 Dec;39(12):2827-8. doi: 10.1128/AAC.39.12.2827.
3
Treatment of tuberculosis and tuberculosis infection in adults and children. American Thoracic Society and The Centers for Disease Control and Prevention.成人及儿童结核病与结核感染的治疗。美国胸科学会及疾病控制与预防中心。
Am J Respir Crit Care Med. 1994 May;149(5):1359-74. doi: 10.1164/ajrccm.149.5.8173779.
4
Synergistic activities of clarithromycin and antituberculous drugs against multidrug-resistant Mycobacterium tuberculosis.克拉霉素与抗结核药物对耐多药结核分枝杆菌的协同活性。
Antimicrob Agents Chemother. 1995 Jul;39(7):1542-5. doi: 10.1128/AAC.39.7.1542.
5
Controlled chemoprophylaxis trials in tuberculosis. A general review.结核病的化学预防对照试验。综述
Bibl Tuberc. 1970;26:28-106.
6
Pyrazinamide susceptibility and amidase activity of tubercle bacilli.结核杆菌的吡嗪酰胺敏感性及酰胺酶活性
Am Rev Respir Dis. 1967 Mar;95(3):461-9. doi: 10.1164/arrd.1967.95.3.461.
7
Inhibition by pyrazinamide of tubercle bacilli within cultured human macrophages.吡嗪酰胺对培养的人巨噬细胞内结核杆菌的抑制作用。
Am Rev Respir Dis. 1986 Nov;134(5):1052-5. doi: 10.1164/arrd.1986.134.5.1052.
8
In vitro and in vivo activities of clarithromycin against Mycobacterium avium.克拉霉素对鸟分枝杆菌的体外及体内活性
Antimicrob Agents Chemother. 1989 Sep;33(9):1531-4. doi: 10.1128/AAC.33.9.1531.
9
Comparative antimycobacterial activities of difloxacin, temafloxacin, enoxacin, pefloxacin, reference fluoroquinolones, and a new macrolide, clarithromycin.双氟沙星、替马沙星、依诺沙星、培氟沙星、对照氟喹诺酮类药物及新型大环内酯类药物克拉霉素的抗分枝杆菌活性比较
Antimicrob Agents Chemother. 1989 Apr;33(4):591-2. doi: 10.1128/AAC.33.4.591.
10
Pyrazinamide and pyrazinoic acid activity against tubercle bacilli in cultured human macrophages and in the BACTEC system.吡嗪酰胺和吡嗪酸在培养的人巨噬细胞及BACTEC系统中对结核杆菌的活性。
J Infect Dis. 1990 Jul;162(1):201-7. doi: 10.1093/infdis/162.1.201.